Overcoming the Road Blocks: Advancement of Block Copolymer Micelles for Cancer Therapy in the Clinic
The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Abstract
With countless preclinical studies on block copolymer micelles (BCMs) successfully demonstrating the superiority of these advanced drug delivery formulations over conventional formulations, it remains somehow discouraging that only a few have reached clinical evaluation and practice. With a critical eye, this review aims to compare and summarize the preclinical and clinical data available on several BCM formulations and to identify their primary role in drug delivery as "carrier" or "solubilizer". This review focuses on polymeric micelles that have reached clinical evaluation and/or are being pursued commercially. Where available, we aim to compare the pharmacokinetics, toxicity, and efficacy data obtained in preclinical studies to identify the factors that likely played a key role in a decision to move these formulations forward from the bench to a first-in-human trial. Finally, we summarize clinical data obtained to date, where available, and conclude with the impact that each formulation has had on patients in terms of safety and efficacy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several polymeric micelle formulations have reached the clinical stage and are either in clinical trials or are approved for human use.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [13]
In the citing paper
“Based on these functionalities derived from the polymer formulations, the overall PK profile of the therapeutic compounds such as maximum systemic concentration, area under the curve (AUC), clearance (CL), volume of distribution (Vd), and biodistribution can be improved [13].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [13]
In the citing paper
“A phase I clinical trial was conducted in South Korea (NCT01336582) and it was reported that Nanoxel® M (70 mg/m2) exhibited an improved drug safety profile compared to the conventional docetaxel formulation in patients with advanced solid tumors [13].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [13]
In the citing paper
“Additionally, amphiphilic polymers used for micelles preparation can interact with biological membranes and display inherent biological activity: it is well known the inhibitory effect of several polymers on the efflux pumps responsible for MDR in chemotherapy [22,23].”
From Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions (2021) · cites this paper as [23]
Citations
Cites
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
Rose, P. G., Bundy, B. N., Watkins, E. B., Thigpen, J. T., Deppe, G., Maiman, M. A., Clarke-Pearson, D. L., & Insalaco, S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904153401502 · Cited by 2,658
Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00171-x · Cited by 1,655
Block copolymer micelles: preparation, characterization and application in drug delivery
Gaucher, G., Dufresne, M.-H., Sant, V. P., Kang, N., Maysinger, D., & Leroux, J.-C. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.09.034 · Cited by 1,498
Nano-engineering block copolymer aggregates for drug delivery
Allen, C., Maysinger, D., & Eisenberg, A. (1999) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/s0927-7765(99)00058-2 · Cited by 1,358
Self-citationEffects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer
Schaake-Koning, C., van den Bogaert, W., Dalesio, O., Festen, J., Hoogenhout, J., van Houtte, P., Kirkpatrick, A., Koolen, M., Maat, B., Nijs, A., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202203260805 · Cited by 1,277
Maeda, H. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.002 · Cited by 1,179
Owen, S. C., Chan, D. P. Y., & Shoichet, M. S. (2012) · Nano Today · doi:10.1016/j.nantod.2012.01.002 · Cited by 911
Block copolymer micelles as vehicles for drug delivery
Kazunori, K., Glenn S., K., Masayuki, Y., Teruo, O., & Yasuhisa, S. (1993) · Journal of Controlled Release · doi:10.1016/0168-3659(93)90172-2 · Cited by 877
Research works printed but not linked: 5
- Harrington K. J., 2001, Clin. Cancer Res., 7, 243
- 10.1002/(sici)1097-0215(19991210)83:6<848::aid-ijc29>3.3.co;2-r · doi:10.1002/(sici)1097-0215(19991210)83:6<848::aid-ijc29>3.3.co;2-r
- Nishiyama N., 2003, Cancer Res., 63, 8977
- Ibrahim N. K., 2002, Clin. Cancer Res., 8, 1038
- Weiss R. B., 1992, Semin. Oncol., 19, 670
Cited by
Polymeric Nanoparticles for Drug Delivery
Beach, M. A., Nayanathara, U., Gao, Y., Zhang, C., Xiong, Y., Wang, Y., & Such, G. K. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00705 · Cited by 1,155
Ghezzi, M., Pescina, S., Padula, C., Santi, P., Del Favero, E., Cantù, L., & Nicoli, S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.031 · Cited by 1,135
Lombardo, D., Kiselev, M. A., & Caccamo, M. T. (2019) · Journal of Nanomaterials · doi:10.1155/2019/3702518 · Cited by 864
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
“Based on these functionalities derived from the polymer formulations, the overall PK profile of the therapeutic compounds such as maximum systemic concentration, area under the curve (AUC), clearance (CL), volume of distribution (Vd), and biodistribution can be improved [13].”
BackgroundInfluentialNguyen, T.-T.-L., Duong, V.-A., & Maeng, H.-J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071103 · Cited by 252
Metadata
- Authors
- Houdaihed, L., Evans, J. C., & Allen, C.
- Affiliations
- University of Toronto (CA)
- Corresponding author
- Allen, Christine
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-05-18
- Volume
- 14
- Issue
- 8
- Pages
- 2503-2517
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2613525853
- Cited by
- 91
- References
- 75
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 9 · 2023: 6 · 2022: 14 · 2021: 14 · 2020: 15 · 2019: 13 · 2018: 9 · 2017: 2
- FWCI
- 0.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (MOP325013)
- GlaxoSmithKline
- U.S. Department of Defense (11964460)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- block copolymer micelles, polymeric micelles, cancer therapy, drug delivery, clinical translation, pharmacokinetics, toxicity, drug solubilization
- MeSH terms
- Drug Carriers, Humans, Micelles, Polymers, Drug Delivery Systems, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overcoming the Road Blocks: Advancement of Block Copolymer Micelles for Cancer Therapy in the Clinic. https://app.cochat.ai/papers/10.1021/acs.molpharmaceut.7b00188
- The paper
- Houdaihed, L., Evans, J. C., & Allen, C. (2017). Overcoming the Road Blocks: Advancement of Block Copolymer Micelles for Cancer Therapy in the Clinic. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.7b00188
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.